Medical device company from Barcelona developing the next generation of neuroelectronic therapies powered by machine learning.

The company’s graphene-brain interfaces have the capability of reading at a resolution never seen before, as well as detecting therapy-specific biomarkers and triggering highly focal adaptive neuromodulation for increased outcomes in personalized neurological therapies. Spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and ICREA, InBrain’s mission is to effectively and innovatively treat patients with epilepsy, Parkinson’s and other brain diseases.